Stem Cell Therapy: What It Is, What It Can (and Can't) Do (2026)
Your body is quietly running a repair operation right now. Old cells die, damaged tissues signal for help, and specialised cells migrate to where they're needed. Stem cell therapy is built on a single ambitious idea: that we can harness — and supercharge — that process.
It sounds almost too good to be true. And depending on who's selling it, it sometimes is.
The global stem cell therapy market is valued at roughly $20 billion in 2026 and is projected to nearly triple by 2036. Thousands of private clinics now offer treatments for everything from arthritic knees to Parkinson's disease. Yet the science supporting most of those treatments is still catching up. Understanding what stem cells genuinely can and cannot do may be the most important thing you read before making a decision about your health.
What Are Stem Cells?
Stem cells are the body's raw material — undifferentiated cells that can divide and develop into more specialised cell types. A stem cell in bone marrow might become a red blood cell. One in muscle tissue might help repair a torn fibre. That flexibility is what makes them so medically interesting.
There are four main types used or studied in medicine today:
Adult stem cells are the most widely used in clinical practice. The two most important subtypes are hematopoietic stem cells, which produce blood and immune cells and form the basis of bone marrow transplants, and mesenchymal stem cells, harvested from bone marrow or fat tissue, which can develop into bone, cartilage, tendon, and fat. Mesenchymal stem cells are the type most commonly injected at private orthopedic clinics.
Perinatal stem cells come from umbilical cord blood, placenta, and other birth tissues. Cord blood stem cells have been used for decades to treat blood and immune disorders. Other cells from these tissues are being studied for potential regenerative and anti-inflammatory uses.
Embryonic stem cells are derived from early-stage embryos. They are powerful — capable of becoming almost any cell type — but they remain largely confined to laboratory research. Their use is ethically contested because obtaining them requires embryo destruction, and no clinical treatments currently use them.
Induced pluripotent stem cells (iPSCs) are adult cells that have been reprogrammed to behave like embryonic cells. Scientists are actively investigating them for degenerative diseases and heart conditions, but virtually all applications are still in research or early trial phases.
What Stem Cell Therapy Is Actually Approved For
This is where most clinic marketing diverges sharply from the regulatory reality.
In the United States, the FDA has approved stem cell therapies for a narrow set of conditions — primarily hematopoietic stem cell transplants used to treat blood cancers such as leukaemia and lymphoma, and certain immune disorders. These treatments are well-established, hospital-based, and backed by decades of evidence.
Nearly everything else — joint injections, anti-ageing treatments, neurological therapies, and the majority of what private clinics advertise — is not FDA-approved. Many of these clinics operate in a regulatory grey area: because they use the patient's own cells and administer them on-site, they are often regulated as medical practice rather than as a drug or biologic, which means oversight is limited.
That does not automatically make them unsafe or ineffective. But it does mean the burden of verification falls on the patient.
What the Research Actually Shows
Joints and orthopedics
Knee osteoarthritis is the most common condition treated at private stem cell clinics, and it has the deepest research base of any non-approved application.
A 2025 meta-analysis of 25 clinical trials involving 1,341 patients found that stem cell injections may produce modest short-term improvements in pain and knee function. A 2020 review of nine trials found stem cells appeared more effective than conservative treatments over 24 months, without significant added side effects — though that study involved only 339 patients.
The takeaway: there is genuine signal in the data, but it is not yet strong enough to make stem cell injections a standard of care. Most experts view them as a reasonable option for early-to-moderate osteoarthritis, not a replacement for surgery in advanced cases.
Neurological conditions
For Alzheimer's, Parkinson's, ALS, multiple sclerosis, and spinal cord injuries, stem cell research is gradually transitioning from animal studies to early human trials. Results so far are cautiously encouraging in some areas and inconclusive in others.
The core challenge is biology. Animal models use standardised injuries and younger, healthier biological environments. Human patients have chronic disease, older tissues, and vastly more variable biology. Most of the dramatic tissue regeneration seen in lab models does not translate directly to people.
How the therapy actually works
The popular image of stem cells physically replacing damaged tissue is largely a myth for most applications. According to sports medicine physician Dr. David Woznica, the primary mechanism of mesenchymal stem cells is not direct transformation but signalling: they release proteins and exosomes that reduce inflammation and encourage the body's own repair processes.
Orthopaedic surgeon Dr. Pamela Mehta puts it plainly: patients typically see functional improvement — less pain, better mobility, reduced inflammation — but full structural replacement of damaged tissue is rare.
A small subset called muse cells can differentiate into other tissue types, but they represent a tiny fraction of what is administered and remain in early research.
Private clinics often combine stem cell injections with complementary treatments such as platelet-rich plasma, hyaluronic acid, and structured rehabilitation. This multi-layered approach may partly explain why some clinic outcomes appear stronger than those seen in tightly controlled trials.
Understanding the Risks
When performed under appropriate protocols, mesenchymal stem cell therapy appears to be broadly safe. Common side effects are mild and temporary: soreness at the injection site, temporary swelling, or a brief inflammatory flare.
Serious risks arise mainly from unregulated or poorly performed procedures. These can include infection, immune reactions, and — in rare but documented cases — tumour formation when cell processing is not properly controlled.
Long-term safety data for most non-approved uses is still limited. The honest answer from most researchers is: we do not yet know what repeated treatments over many years may do.
A Real Patient's Experience — and Its Limits
In 2010, former professional athlete Greg Novacheck suffered a catastrophic hamstring tear. His biceps femoris tore completely in half, leaving a visible gap in the muscle. Multiple surgeons told him repair was unlikely to succeed.
After receiving stem cell therapy combined with platelet-rich plasma through a South Florida clinic, MRI scans taken 16 days later showed the muscle had reconnected. "For me, it was life-changing," he told The Epoch Times. "But I'm also very aware that my outcome may not be typical."
That caveat matters enormously. A single dramatic recovery is not clinical evidence. Individual biology, injury type, age, general health, and the quality of the clinic's protocols all influence outcomes. Stories like Novacheck's drive patients toward private clinics — which is precisely why understanding their limits is so important.
How to Evaluate a Stem Cell Clinic
If you are considering treatment, the following framework will help you separate credible practices from those trading on hype.
Look for physician-led expertise. The clinic should be run by doctors with relevant specialty training — orthopaedic surgeons for joint conditions, neurologists for neurological applications. They should clearly explain the cell source, processing method, and realistic expectations. Anyone promising to "cure" arthritis or "fully regenerate" cartilage should be treated with immediate scepticism.
Ask about protocols and follow-up. Credible clinics use standardised, well-characterised cell sources and track patient outcomes over time. Ask whether they can share aggregate outcome data — not just testimonials.
Red flags to watch for: guaranteed outcomes, no discussion of risks or limitations, vague information about where cells come from, and pressure to commit to large upfront fees without thorough consent documentation.
Manage your timeline expectations. Tissue healing is slow regardless of the intervention. Most treatments involve multiple sessions, and meaningful improvement — if it comes — typically develops over months, not days.
Frequently Asked Questions
Is stem cell therapy legal? Yes, in most countries. In the US, hematopoietic stem cell transplants for blood disorders are FDA-approved. Many private orthopedic and regenerative clinics operate legally in a regulatory grey area, using the patient's own cells under medical practice rules rather than as FDA-approved biologics.
How much does stem cell therapy cost? Costs vary widely. Private clinic treatments typically range from $3,000 to $15,000 or more per session, and most are not covered by insurance. FDA-approved bone marrow transplants for blood cancers are covered when medically necessary.
What conditions is stem cell therapy used for? Approved uses centre on blood cancers and immune disorders. Private clinics commonly treat knee osteoarthritis, tendon injuries, and sports injuries. Research is also underway for neurological conditions including Parkinson's, ALS, and spinal cord injury — but these applications remain experimental.
What is the difference between stem cell therapy and PRP? Platelet-rich plasma (PRP) uses concentrated growth factors from your own blood to promote healing, but contains no stem cells. Stem cell therapy introduces actual stem cells to target tissues. Many clinics combine both, as the treatments may have complementary mechanisms.
Are stem cells from umbilical cord blood different from injected stem cells? Yes. Cord blood stem cells are hematopoietic and used primarily for blood and immune disorders. The mesenchymal stem cells most commonly injected at orthopedic clinics come from bone marrow or fat tissue and have different properties and applications.
The Bottom Line
Stem cell therapy sits at a genuine frontier of medicine. For blood cancers and immune disorders, it has saved lives for decades. For orthopedic conditions, early evidence is promising, though not yet definitive. For neurological diseases, it remains largely experimental.
The science is real. The hype is also real. The gap between them is where patients most need clear information.
"Biology and disease stage matter more than marketing claims," says Dr. Mehta. "Earlier disease, better tissue quality, and overall health tend to produce better results."
The clinics making the most modest claims, backed by the most transparent data, are almost always the most trustworthy.
Related:
- Stem cell therapy for knee osteoarthritis: what the clinical trials show
- What is platelet-rich plasma (PRP) and how does it differ from stem cells?
- Stem cell therapy for Parkinson's disease: where is the research now?
- How to spot stem cell clinic red flags: a patient's checklist
- Mesenchymal stem cells vs. hematopoietic stem cells: what's the difference?
Comments